Double Plasma Molecular Adsorption System: A Modality of Treating Fulminant Hepatic Failure

HM Surya

doi:10.5005/jp-journals-10089-0064

SEARCH WITHIN CONTENT

Online First

Double Plasma Molecular Adsorption System: A Modality of Treating Fulminant Hepatic Failure

HM Surya

Keywords : Artificial liver support system, BS330, Double plasma molecular adsorption system, Fulminant hepatic failure, HA330

Citation Information : Surya H. Double Plasma Molecular Adsorption System: A Modality of Treating Fulminant Hepatic Failure. 2023; 2 (1):42-43.

DOI: 10.5005/jp-journals-10089-0064

License: CC BY-NC 4.0

Published Online: 23-08-2023

ARTICLE
REFERENCES

Abstract

Fulminant hepatic failure (FHF) secondary to hepatitis A is a relatively rare but sometimes fatal condition. Treatment is largely supportive, with definitive treatment involving a liver transplant. Among the newer modalities developed to support the patient is the double plasma molecular adsorption system (DPMAS), which works on the principle of hemoadsorption. The system consists of two hemadsorption cartridges containing porous resin beads which adsorb toxins such as bilirubin and ammonia. We report such a case of FHF secondary to hepatitis A, which was treated with DPMAS.

HTML PDF Share

Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher 2019;34(4):392–398. DOI: 10.1002/jca.21690
Ankawi G, Fan W, Pomarè Montin D, et al. A new series of sorbent devices for multiple clinical purposes: current evidence and future directions. Blood Purif 2019;47(1-3):94–100. DOI: 10.1159/000493523
Bai W, Yao C, Mao D, et al. The clinical efficacy of double plasma molecular absorption system combined with plasma exchange in the treatment of acute-on-chronic liver failure: a systematic review and meta-analysis. J Healthc Eng 2022;2022:3139929. DOI: 10.1155/2022/3139929

PDF Share